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The use of neuromodulation for pain relief is among the fastest-growing areas of medicine, involving many diverse specialties
and impacting on hundreds of thousands of patients with numerous disorders worldwide. As the evidence of eﬃcacy improves,
the interest in spinal cord stimulation (SCS) will increase because it is minimally invasive, safe, and a reversible treatment
modality with limited side eﬀect proﬁle. While the mechanism of action evades complete understanding, the technological
improvements have been considerable and current neuromodulation developments have been coupled with the rapid growth
of the neuromodulation device industry resulting in the development of the next-generation neuromodulation systems. The
development, the newest technicaliti and the future for the clinical application of spinal cord stimulation (SCS) are reviewed
here.
1.Introduction
Neuromodulation is among the fastest-growing areas of
medicine, involving many diverse specialties and impacting
on hundreds of thousands of patients with numerous dis-
orders worldwide [1]. Historically, electricity, either in the
form of the torpedo ﬁsh or man-made electrotherapy, has
been used to try and cure various ailments [2]. For ex-
ample, in the middle of the 18th century “electroanalgesia”
became advocated for the treatment of angina pectoris, gout,
headaches, pleuritic pain, and sciatica. However, by the 20th
century the enthusiasm for the medical use of electricity
became associated with “quackery” [3] and was banned
from clinical practice. In 1965 Melzack and Wall presented
the “Gate Theory” [4], which postulated that stimulation
of nonpainful stimuli can inhibit painful aﬀerence, thereby
oﬀering the opportunity to align basic research with the
clinical application of electricity which has resulted in the
development of neuromodulation techniques as we know
them today [5–7]. While the mechanism of action evades
complete understanding, the technological improvements
have been considerable and current neuromodulation devel-
opments have been coupled with the rapid growth of the
neuromodulation device industry resulting in the develop-
ment of the next-generation neuromodulation systems. The
development, the newest technicalities, and the future for
the clinical application of spinal cord stimulation (SCS) are
reviewed here.
2. Principles of Neuromodulation
Essentially there are two components of a fully implanted
SCS system: the electrodes (or lead) and an implantable
pulse generator (IPG). In SCS the placement of epidural
electrodes is generally targeted at the dorsal column of the
spinal cord; however, in patients with segmental pain (single
dermatome), stimulation is focused at the corresponding
dorsal root. This is where the ascending tracts pass without
decussation to the gracile and cuneate nuclei of the medulla
oblongata. These tracts are composed of a wide range of
ﬁberdiameterswhicharethecentralprocessesoftheprimary
aﬀerent neurons located in the spinal ganglia. As the tracts
ascend,theyreceiveaccessionfromthedorsalroots,resulting
in a somatotopic organization [6]. The recruitment of ﬁbers
is correlated directly with the diameter of the ﬁber and
inversely with the distance between the electrode contacts2 Anesthesiology Research and Practice
and the ﬁbers [6]. Hence the thickness of the cerebrospinal
ﬂuid layers [8], the individual anatomy, and the electrodes
each inﬂuence the recruitment of the dorsal column [8–11]
and dorsal root ﬁbers [12].
In addition the large diameter ﬁbers of the dorsal root
and dorsal column have diﬀerent orientation with respect
to the spinal anatomy and hence in a diﬀerent position in
the electrical ﬁeld evoked by the stimulation pulses. Further-
more, the distance between the electrode and the thickness
of the dorsal cerebral spinal ﬂuid (dCSF) layer inﬂuences
the sensitivity of the ﬁbers to the stimulation. Computer
modeling predicted that a “bipolar” or a narrow guarded
cathode programming sequence selectively stimulates dorsal
cord ﬁbers when the dCSF is small. In contrast, dorsal root
stimulation is favored the most in “monopolar” stimulation
when dCSF is wide [8–10]. In pain patients with segmental
pain, stimulation can be focused on dorsal root ﬁbers of the
corresponding dermatome, whereas in patients with com-
plex pain a multitude of dorsal column ﬁbers related to
multiple dermatomes should be stimulated. The results of
these computer-based model studies led to the development
of electrode arrays with similar geometric properties [13].
Once an electrode/lead is suitability positioned, the most
common way to increase the intensity of the stimulation is
to increase the amplitude (i.e., the current, the voltage pro-
vided); increasing the pulse rate beyond physiological limits
(approximately 300 pulse per second) is not traditionally
seen as providing therapeutic beneﬁt as neural transmission
may become blocked. Similarly the pulse width was tradi-
t i o n a l l ys e ta t2 0 0µs in order to provide adequate amplitude
while conserving the energy of the battery. With modern
technological advancements, these concepts are now facing
aninterestingchallengeandmayinﬂuencethefutureofsome
aspects of SCS.
3. New Electrode Contactand Lead Design
Remarkable technological advances have been achieved in
terms of electrode contact/lead design. Firstly, the new mul-
ticontact arrays available in traditional and ﬁve-column
paddle leads (St. Jude Medical, Inc, USA) have resulted in
theabilitytoprovideimprovedprogrammablecapabilityand
possible treatment outcome. Mathematical modeling has
highlighted the potential beneﬁts of tight-electrode spacing
in electrode contact design whereby gaps in stimulation are
avoided(BostonScientiﬁcNeuromodulation,Valencia,Calif,
USA).Indeed,toobtainlargeparaesthesiacoverage,allactive
contacts (anodes and cathodes at one or more arrays) should
be closely spaced.
In the beginning SCS stimulation involved only a single
channel, which meant that the stimulator had only one ca-
thodal voltage output and one anodal voltage output, each
one being connected to one or more lead contacts. Only
recently multichannel systems have been produced (Boston
Scientiﬁc Neuromodulation, Valencia, Calif, USA). In these
systems any active lead contact is driven independently with
a preprogrammed current pulse. The only condition is that
the sum of all cathodal and anodal currents is zero and that
all pulses are synchronized. The number of settings increases
exponentially from 50 combinations with four electrode
contacts to tens of millions when 16 electrode contacts
are available [14]. Intuitively one would be forgiven for
assumingthatwiththenewermulticontactorthemultichan-
nel systems [15] signiﬁcant clinical improvements would
follow, but these technical advantages have not necessarily
improved treatment in all indications [16]. In fact, despite
the large number of contacts available, the actual number
of active contacts will generally be small (bipole, tripole, or
quadruple).
Secondly, the improved “steerability” of the leads com-
bined with a variety of stylets to guide the positioning of the
electrodes has resulted in a preference for the less invasive
percutaneous insertion of the leads into the epidural space
via a Touhy needle. The design of the Epiducer lead delivery
system (St. Jude Medical, Inc, USA) is proposed to allow
the advancement of a paddle lead without the use of a
laminectomy.
Importantly, the improved ﬂexibility of the leads has not
compromised the lead fracture rate; this has fallen from 6%
in earlier studies [17]t o3 %[ 18]. Lead migration usually
occurs in the ﬁrst 12 months of implantation and varies
between 8% [19] and 27% [20]. Migration may be related
to the anchoring technique and not the actual lead design.
The industry is striving to identify a solution to migration
throughthedevelopmentofconsistentandveriﬁableanchor-
ing technology. Another development based on computer
modeling is transverse tripolar stimulation, allowing the
mediolateral steering of the electric ﬁeld to correct for an
inaccurate lead position [21]. Transverse tripolar steering
principle led to even more complex conﬁgurations like the
development of a 5-column paddle lead (Penta, St. Jude
Medical).
A third technical challenge that remains is the lack
of compatibility of the leads with magnetic resonance
imaging (MRI) and radiofrequency diathermy which can be
a signiﬁcant limitation for some patients. Metallic implants
(including nonferrous) are prone to heating when exposed
to MRI or diathermy. In vitro comparisons showed that
temperature changes near SCS electrodes were higher than
those found with other metallic implants, reaching up to
4.88◦C/s−1 [22]. While the safe use of MRI in patients with
SCS leads in place has been reported [23], so too has nonre-
versible damage and death [20, 24]. Most manufacturers are
addressing the issue, and safer leads are expected.
4. IPG Advancements
Originally regarded as just a battery, the IPG has now
evolved to become an engineer’s paradise. Long gone are
the nickel-cadmium systems which are replaced by lithium-
based batteries thereby prolonging the lifespan of the device.
With the advent of complex stimulation settings involving
the activation of an increasing number of contacts the
premature exhaustion of the battery is avoided by using
automatic nocturnal, time-cycled, or manual interruption of
stimulation. The industry has developed a variety of newAnesthesiology Research and Practice 3
generation of compact rechargeable IPGs to meet the new
requirements of SCS; thereby, energy consumption becomes
less of a problem.
As previously mentioned the recruitment of dorsal horn
ﬁbers is correlated inversely with the distance between the
electrodecontactandtheﬁber[6].Hencethethicknessofthe
cerebrospinal ﬂuid layers [8] the recruitment of the dorsal
column [8–11] and dorsal root ﬁbers [12]. Therefore as
electrode/leads placement varies and stimulation intensity
can vary depending on the position of the patient (e.g.,
supineorstanding)tosuchanextentthatpatientscannotuse
the IPG without manually changing the program in order to
avoid painful overstimulation.
The RestoreSensor (Medtronic Inc, USA) is the ﬁrst
implantable neurostimulator for spinal cord stimulation
(SCS) that automatically adapts stimulation settings in re-
sponse to position changes and provides objective patient
activity data. The adaptive SCS is based on acceleration
sensor that enables chronic motion sensing in battery-
powered applications. It is robust to shock and represents
theﬁrstpractical,packaged,three-axisaccelerometersuitable
forchronicphysiologicalmeasurements.Thesensor’sperfor-
mance is also desirable for more general micropower appli-
cations like package tracking, vibration, and tilt detection.
Initial results from the Testing RestoreSensor Usability
and Satisfaction (TRUST) survey [25] in 30 patients, mainly
suﬀering from predominant leg pain due to failed back
surgery syndrome or complex regional pain syndrome type
I, followed up over a 10-week period are very promising.
80% of patients reported more eﬀective pain relief. Use
of the patient programmer became less diﬃcult, and less
necessary, with adaptive stimulation. Adaptive stimulation
had a positive eﬀect on sleep quality in all patients, which
may have led to a perception of greater sleep quantity. In
total, 58% of patients reported the ability to perform more
activities with the therapy (e.g., standing, walking, sleeping,
and staying in a particular position longer). Overall patient
satisfaction was 97% at the end of the 10-week follow-up
period [25].
5. Modiﬁcation of the Pulse Width
In SCS, the pulse amplitude is usually the focus of stim-
ulation control as it is intuitively understood by clinician
and patient alike [26–29]. With advances in SCS technology,
particularly rechargeable IPG implantable devices, pulse
width (PW) programming ranges of now match that of
older radiofrequency systems (with programmability up to
1000µs). Traditionally PW was only changed when other
parameter adjustments fail to achieve therapeutic goals. In
neurostimulation the pulse amplitude and width relate di-
rectly to the depolarization of the cell membrane and are
therefore critical parameters for determining the locus of
excited tissue [30]. The value of PW programming was
investigated in 19 subjects who had a fully implanted SCS
in place for over 3 months to treat chronic intractable low
back and/or leg pain. It was shown that the baseline median
PW parameter was 295µs (range 242–326µs) with a median
amplitude of 2.5mA (1.3–3.3mA). Following independent
modiﬁcation of the PW, the median PW of all patients’ pro-
grams increased to 400µs, approximately 48% higher (P =
0.01) and showed a signiﬁcant increase in the paraesthesia-
pain overlap (56%, P = 0.04). It was estimated that 10/19
patients appeared to have greater paraesthesia coverage, 7/19
patients selected the new PW programs, and 8/19 patients
appeared to display a “caudal shift” of paraesthesia coverage
with increased PW [31].
Mathematical modelling suggests that the mechanism
behind such paraesthesia steering is due to the diﬀerent
selectivity of PW for larger and smaller ﬁbers. The model
considered incorporated realistic ﬁber size, density, and
distributions in the dorsal columns, based upon human
anatomic data. With a greater relative density of smaller
ﬁberslocated more medial in the dorsal columns, an increase
in PW will recruit smaller ﬁbers more readily and thus result
ingreatermidlineaxonrecruitment.Clinically,thisappeared
to manifest as a caudal shift in paraesthesia. In summary
variable PW programming in SCS appears to have clinical
value, demonstrated by some patients improving their
paraesthesia-pain overlap, as well as the ability to increase
and even “steer” paraesthesia coverage [31].
6. High-FrequencyStimulation
Although SCS is a recommended treatment for patients with
failed back surgery syndrome (FBSS) [32], if paraesthesia
over the lumbar dermatomes cannot be obtained, then axial
l o wb a c kp a i ni sv e r yd i ﬃcult to treat and clinical results
are poor [33]. Ongoing multicentred European prospective
trials [34] using dual octapolar, percutaneous leads placed
sequentially near anatomic midline and connected to a re-
chargeable IPG capable of delivering waveforms with fre-
quencies up to 10kHz. (Nevro, Menlo Park, Calif) have
shown that of 34 cases with full implantation the average
back pain VAS decreased by 77% (8.9cm baseline to 2.0cm
at 6 months, P < .001) and leg pain VAS decreased by 82% at
6-month follow-up. (5.5cm baseline to 0.7cm at 6 months,
P < .001). In addition the average Oswestry Disability Index
score decreased by 36% (from 58 to 37, P < .001). This
approach is novel for several reasons: (a) the use of high-
frequency stimulation provides sustained analgesia in a
previously diﬃcult patient cohort without paraesthesia—
thus adequate axial low back pain relief is achieved without
the overwhelming leg sensation one would have expected
by increasing the frequency using a traditional IPG; (b)
anatomical placement of the leads is possible and intraop-
erative paraesthesia mapping is avoided; (c) it has decreased
programming requirements; (d) continued use of the system
independent of position including night-time use is possible.
To date, no adverse eﬀect of such high-frequency stimulation
has been reported however, the clinical outcome in the
longer term is awaited. Pre-clinical studies in goats who
received 10 days of continuous stimulation at amplitudes
up to the sensory/motor threshold showed no diﬀerence
in the behaviour or spinal cord neural histology between
the therapy and control groups. Why such stimulation has4 Anesthesiology Research and Practice
this remarkable eﬀect still remains to be understood and
may inﬂuence our approach to this co-cohort heretofore un-
satisfactorily managed with conventional SCS technology.
7. New ClinicalApplications
There are several established indications for SCS such as
neuropathic back and leg pain, complex regional pain
syndrome, spinal cord injury, and ischemic pain (vascular
and angina pectoris). While it is beyond the remit of this
paper to discuss each clinical indication, there is a growing
databaseofclinical-basedevidencetosupporttheuseofSCS.
The economic evaluation in these areas is limited but the
initial costs of SCS is generally both more eﬀective and less
costly then conventional management over a period of 3–
5y e a r s[ 33]. Unfortunately SCS is regarded as a last-resort
option by many healthcare providers, and the real economic
beneﬁts may lie in the earlier introduction of the technique.
The recognition of new treatment modalities and the
new application of SCS techniques will redeﬁne our under-
standing of the pathophysiological concepts involved in
diﬀerent medical conditions. For example, painful bladder
syndrome/interstitial cystitis and diﬀuse chronic abdom-
inal/pelvic pain may be considered as neuropathic pain
thereby oﬀering the potential for exciting development. The
evidence that cervical SCS increases cerebral blood ﬂow
(CBF) may lead to a role in cerebral ischemia. The modiﬁ-
cation of the autonomic system, particularly its sympathetic
component by SCS, suggests that body functions under
signiﬁcant autonomic control could be subjected to mod-
ulation. It is suggested that in the future bronchospasm,
gastrointestinal motility, and possibily metabolic disorders
could become the focus of neuromodulation [35].
8. Conclusion
Modern medicine requires that any treatment modality is
based on rational knowledge and well-documented theo-
ries; however, some conditions, particularly those involving
chronic pain, often remain imprecise. SCS may be one
of the few examples of a treatment that has signiﬁcantly
contributed to a change in attitudes and providing satis-
factory relief to patients who in the past would have been
left untreated.
Spinal cord stimulation has signiﬁcant implications for
the healthcare system oﬀering a safe reversible treatment
modality with a limited side eﬀect proﬁle. To ensure the
deliverance of a high-standard quality of care spinal cord
stimulation should be provided in small well-resourced cen-
tres able to address the aftercare needs of this patient cohort.
Cost-eﬀectivenessandeﬃcacyarefundamentalifSCSistobe
accepted as the therapy of choice by the public, physicians,
and the healthcare decision makers. Earlier introduction of
the technique may prove to be critical. Research into the
mechanism of pain, the diseases, and the action of SCS
requires randomized control trials (RCTs). The inability (a)
to blind patients (owning to the paraesthesia), (b) to select
a comparative therapy (medical, surgical, rehabilitation),
and/or (c) to address the ethical implications to participate
in a trial are speciﬁc issues in the design of such a RCT.
As the evidence of eﬃcacy improves and the number of
indications increases, the interest in the neuromodulation
and SCS will undoubtedly increase. SCS is minimally inva-
sive,safe,andreversibletreatmentmodalitywithlimitedside
eﬀect proﬁle. It is only through the combined eﬀorts of the
biomedical industry, basic science researchers, and frontline
healthcare providers will the technological advancements
alreadymadeinthisareacontinuetomakesigniﬁcantclinical
impact on the patients of tomorrow.
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